Scinus Group, a biotechnology company, has secured €3 million in strategic funding to accelerate the international rollout of its Osilaris™ cell expansion platform.
The investment round was led by Myosotis Investments, with participation from existing shareholders including the company’s founders and the Demcon Innovation Fund. The funding will support commercialization efforts and further development of the company’s bioreactor technology for cell therapy manufacturing.
What The Company Does
Scinus develops bioreactor technologies designed to support the production of advanced cell therapies.
The company’s core product, the Osilaris™ Platform, is an automated and enclosed bioreactor system used to cultivate and expand therapeutic cells. The platform is designed to support the manufacturing of clinical-grade cell therapies while maintaining strict environmental control and minimizing contamination risks.
By combining multiple processing steps within a single automated system, the platform reduces the need for manual intervention and simplifies complex cell expansion workflows.
The technology is compatible with a wide range of therapeutic applications, including CAR T-cell therapies, CAR-TCR therapies, tumor-infiltrating lymphocytes, mesenchymal stem cells, induced pluripotent stem cells, organoids, viral vector production, and extracellular vesicle manufacturing.
Advertisement
Market Context / Industry Background
Cell therapies have emerged as a promising approach for treating a variety of diseases, including cancers and regenerative conditions. However, manufacturing these therapies at scale remains one of the major challenges facing the industry.
Many current production processes involve complex laboratory procedures that require specialized facilities and extensive manual handling. As more cell therapies move beyond early-stage clinical trials, the ability to produce cells consistently and efficiently becomes increasingly important.
Automated and closed manufacturing platforms are being developed to address these challenges. Such systems aim to improve production consistency, reduce contamination risk, and lower operational costs while enabling larger-scale manufacturing.
Improving manufacturing infrastructure is considered essential for expanding patient access to advanced cell therapies and enabling broader commercial adoption.
Founder / Investor Commentary
Scinus Group was founded in 2016 by Prof. Dr. Joost de Bruijn, Prof. Dr. Clemens van Blitterswijk, and FrankJan van der Velden after separating from Xpand Biotechnology.
The company’s leadership believes scalable manufacturing systems will be critical for enabling the widespread use of advanced cell therapies.
Dr. Erik Vossenaar, currently Managing Director and soon to become CEO, said the new funding will help the company strengthen its organizational structure and commercial operations.
“This investment brings Scinus to the next level of organisational maturity,” Vossenaar said. “With a strengthened governance structure and a market-ready GMP-compliant platform, we are well positioned to execute our commercial rollout strategy in key markets.”
Dr. Wietse Mulder, founder and managing partner at Myosotis Investments, said the platform addresses several manufacturing bottlenecks in the cell therapy sector.
“Advanced cell therapies require robust and scalable manufacturing solutions,” Mulder said. “Scinus has developed a differentiated platform that addresses key challenges in control, scalability and cost efficiency.”
Growth Plans / Use Of Funds
Scinus plans to use the new funding to accelerate the global commercialization of its Osilaris™ platform and expand deployments in key life sciences markets.
The platform is already in use at several academic Advanced Therapy Medicinal Products (ATMP) manufacturers and contract development and manufacturing organizations across Europe.
In addition to scaling commercial adoption, the company intends to strengthen its governance and operational capabilities as it prepares for further growth.
As part of this process, Dr. Erik Vossenaar will assume the role of CEO, while Dr. Janeska de Jonge will join the board as a non-executive director representing Myosotis Investments. A third board member is expected to be appointed in the near future.
About Scinus
Scinus Group is a biotechnology company developing manufacturing technologies for advanced cell therapies. Founded in 2016 and headquartered in Utrecht, the company builds automated bioreactor systems designed to cultivate and expand therapeutic cells under controlled conditions. Its Osilaris™ platform aims to improve the scalability, consistency, and efficiency of cell therapy manufacturing for clinical and commercial applications.
